Objective
This study evaluated the use of bioactive glass, PerioGlas®, after retrograde filling with Super EBA™ cement in the treatment
of periapical bone destruction.
Study design
Healing outcomes were followed up after endodontic surgery in 186 teeth. Outcomes were divided into two groups according to
follow-up time: short- and long-term. The EBA™ group (n = 110) underwent endodontic surgery and retrograde filling with EBA™ cement. In the EBA™ + PerioGlas® group (n = 76), PerioGlas® was embedded in the bone cavity after retrograde filling.
Results
The success rate in the EBA™ + PerioGlas® group was 72% compared with 56% in the Super EBA™ group at the short-term follow-up
and 74% and 84%, respectively, at the long-term follow-up. Healing of periapical bone destruction classified as uncertain
at the short-term follow-up was considered successful in two out of three cases at the long-term follow-up.
Conclusion
This study found that PerioGlas® as bone substitute did not significantly improve endodontic healing outcome.
Keywords Bone graft evaluation - Bone regeneration - Endodontic surgery - PerioGlas® - Retrograde filling